Laura J. van’t Veer

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Risk-Based vs Annual Breast Cancer Screening

  JAMA · 2025-12-12 · 34 citations

• Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerPreprint

  medRxiv · 2025-08-27

• 5MO Pretreatment circulating tumor (ct)DNA predicts metastatic recurrence in patients (pts) with high-risk early breast cancer (eBC) enrolled in the I-SPY 2 trial

  ESMO Open · 2025-05-01 · 1 citations

• LBA2 Rates of pathologic complete response after VV1 and cemiplimab (alone and in treatment sequence-strategy) in the neoadjuvant setting: Results from the I-SPY 2.2 trial

  ESMO Open · 2025-05-01

• Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer

  Breast Cancer Research and Treatment · 2024-12-03 · 4 citations

• Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study

  Tomography · 2024-11-20 · 2 citations

• Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

  Annals of Oncology · 2024-10-30 · 25 citations

• 314P The impact of changes in tumor mutational landscape during neoadjuvant therapy on tumor-informed ctDNA testing in breast cancer patients

  Annals of Oncology · 2024-09-01 · 1 citations

• LBA16 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) in the neoadjuvant setting: Results from the I-SPY 2.2 trial

  Annals of Oncology · 2024-09-01

• LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial

  Annals of Oncology · 2024-09-01 · 1 citations

• 315P Long-term tamoxifen benefit in pre- and postmenopausal patients of high and low risk with luminal A and B breast cancer

  Annals of Oncology · 2024-09-01

• 316P Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials

  Annals of Oncology · 2024-09-01